On November 5, Nasdaq approved and launched the Canary Staked INJ ETF, the first Injective staked ETF, under ticker INJC. Issuer Canary Capital plans to stake at least 90% of the fund’s INJ holdings under normal conditions, with BitGo as custodian. Staking rewards are reflected in the fund’s net asset value, and the sponsor fee is 1.10%. INJ rose 6% following the Nasdaq listing.
Nasdaq approved the Canary Staked INJ ETF, allowing investors exposure to Injective while earning staking rewards through a regulated fund structure.
Read the full storyNasdaq has greenlit the first-ever Injective staked ETF, providing traditional investors with exposure to the ecosystem through standard brokerage accounts.